Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help
Search by PDB author
3CEJ
DownloadVisualize
BU of 3cej by Molmil
Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE2865
Descriptor: 1-{2-[3-(2-Chloro-4,5-difluoro-benzoyl)-ureido]-4-fluoro-phenyl}-piperidine-4-carboxylic acid, Glycogen phosphorylase, liver form, ...
Authors:Wendt, K.U, Dreyer, M.K, Anderka, O, Klabunde, T, Loenze, P, Defossa, E, Schmoll, D.
Deposit date:2008-02-29
Release date:2008-05-27
Last modified:2020-07-29
Method:X-RAY DIFFRACTION (3.3 Å)
Cite:Thermodynamic characterization of allosteric glycogen phosphorylase inhibitors.
Biochemistry, 47, 2008
3CEM
DownloadVisualize
BU of 3cem by Molmil
Human glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE9423
Descriptor: 1-(2-carboxyphenyl)-7-chloro-6-[(2-chloro-4,6-difluorophenyl)amino]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, Glycogen phosphorylase, liver form, ...
Authors:Wendt, K.U, Dreyer, M.K, Anderka, O, Klabunde, T, Loenze, P, Defossa, E, Schmoll, D.
Deposit date:2008-02-29
Release date:2008-05-27
Last modified:2020-07-29
Method:X-RAY DIFFRACTION (2.47 Å)
Cite:Thermodynamic characterization of allosteric glycogen phosphorylase inhibitors.
Biochemistry, 47, 2008
3CEH
DownloadVisualize
BU of 3ceh by Molmil
Human liver glycogen phosphorylase (tense state) in complex with the allosteric inhibitor AVE5688
Descriptor: 2-(N-MORPHOLINO)-ETHANESULFONIC ACID, 4-[3-(2-Chloro-4,5-difluoro-benzoyl)ureido]-3-trifluoromethoxybenzoic acid, Glycogen phosphorylase, ...
Authors:Wendt, K.U, Dreyer, M.K, Anderka, O, Klabunde, T, Loenze, P, Defossa, E, Schmoll, D.
Deposit date:2008-02-29
Release date:2008-05-27
Last modified:2020-07-29
Method:X-RAY DIFFRACTION (2.8 Å)
Cite:Thermodynamic characterization of allosteric glycogen phosphorylase inhibitors.
Biochemistry, 47, 2008
1LPK
DownloadVisualize
BU of 1lpk by Molmil
CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 125.
Descriptor: 1-(3-CARBAMIMIDOYL-BENZYL)-1H-INDOLE-2-CARBOXYLIC ACID 3-CARBAMIMIDOYL-BENZYLESTER, Blood coagulation factor Xa, CALCIUM ION
Authors:Schreuder, H.A, Loenze, P, Brachvogel, V, Liesum, A.
Deposit date:2002-05-08
Release date:2003-05-08
Last modified:2021-10-27
Method:X-RAY DIFFRACTION (2.2 Å)
Cite:Design and Quantitative Structure-Activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa
J.Med.Chem., 45, 2002
1LQD
DownloadVisualize
BU of 1lqd by Molmil
CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 45.
Descriptor: 1-(3-CARBAMIMIDOYL-BENZYL)-4-METHYL-1H-INDOLE-2-CARBOXYLIC ACID 3,5-DIMETHYL-BENZYLAMIDE, Blood coagulation factor Xa, CALCIUM ION
Authors:Schreuder, H.A, Loenze, P, Brachvogel, V, Liesum, A.
Deposit date:2002-05-10
Release date:2003-05-10
Last modified:2011-07-13
Method:X-RAY DIFFRACTION (2.7 Å)
Cite:Design and Quantitative Structure-Activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa
J.Med.Chem., 45, 2002
1O4P
DownloadVisualize
BU of 1o4p by Molmil
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78791.
Descriptor: 2-PHENYLMALONIC ACID, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC
Authors:Lange, G, Loenze, P, Liesum, A.
Deposit date:2003-06-15
Release date:2004-02-17
Last modified:2023-08-16
Method:X-RAY DIFFRACTION (1.9 Å)
Cite:Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
J.Med.Chem., 46, 2003
1O4Q
DownloadVisualize
BU of 1o4q by Molmil
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU79256.
Descriptor: PHENYL(SULFO)ACETIC ACID, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC
Authors:Lange, G, Loenze, P, Liesum, A.
Deposit date:2003-06-15
Release date:2004-02-17
Last modified:2023-08-16
Method:X-RAY DIFFRACTION (1.7 Å)
Cite:Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
J.Med.Chem., 46, 2003
1O4J
DownloadVisualize
BU of 1o4j by Molmil
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH ISO24.
Descriptor: PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC, [(4-ETHYLPHENYL)AMINO]CARBONYLPHOSPHONIC ACID
Authors:Lange, G, Loenze, P, Liesum, A.
Deposit date:2003-06-15
Release date:2004-02-17
Last modified:2023-08-16
Method:X-RAY DIFFRACTION (1.7 Å)
Cite:Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
J.Med.Chem., 46, 2003
1O4D
DownloadVisualize
BU of 1o4d by Molmil
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78262.
Descriptor: 2-FORMYLPHENYL DIHYDROGEN PHOSPHATE, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC
Authors:Lange, G, Loenze, P, Liesum, A.
Deposit date:2003-06-15
Release date:2004-02-17
Last modified:2023-08-16
Method:X-RAY DIFFRACTION (1.85 Å)
Cite:Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
J.Med.Chem., 46, 2003
1O43
DownloadVisualize
BU of 1o43 by Molmil
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU82129.
Descriptor: PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC, [4-((1Z)-2-(ACETYLAMINO)-3-{[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]AMINO}-3-OXOPROP-1-ENYL)-2-FORMYLPHENYL]ACET IC ACID
Authors:Lange, G, Loenze, P, Liesum, A.
Deposit date:2003-06-15
Release date:2004-02-17
Last modified:2023-08-16
Method:X-RAY DIFFRACTION (1.5 Å)
Cite:Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
J.Med.Chem., 46, 2003
1O49
DownloadVisualize
BU of 1o49 by Molmil
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU85493.
Descriptor: PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC, {4-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-PHOSPHONO-PHENOXY}-ACETIC ACID
Authors:Lange, G, Loenze, P, Liesum, A.
Deposit date:2003-06-15
Release date:2004-02-17
Last modified:2023-08-16
Method:X-RAY DIFFRACTION (1.7 Å)
Cite:Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
J.Med.Chem., 46, 2003
1O4G
DownloadVisualize
BU of 1o4g by Molmil
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH DPI59.
Descriptor: HYDROXY(1-NAPHTHYL)METHYLPHOSPHONIC ACID, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC
Authors:Lange, G, Loenze, P, Liesum, A.
Deposit date:2003-06-15
Release date:2004-02-17
Last modified:2023-11-15
Method:X-RAY DIFFRACTION (1.55 Å)
Cite:Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
J.Med.Chem., 46, 2003
1O4M
DownloadVisualize
BU of 1o4m by Molmil
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH MALONICACID.
Descriptor: MALONIC ACID, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC
Authors:Lange, G, Loenze, P, Liesum, A.
Deposit date:2003-06-15
Release date:2004-02-17
Last modified:2023-08-16
Method:X-RAY DIFFRACTION (1.6 Å)
Cite:Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
J.Med.Chem., 46, 2003
1O4H
DownloadVisualize
BU of 1o4h by Molmil
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU79072.
Descriptor: 2-CYANOQUINOLIN-8-YL DIHYDROGEN PHOSPHATE, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC
Authors:Lange, G, Loenze, P, Liesum, A.
Deposit date:2003-06-15
Release date:2004-02-17
Last modified:2023-08-16
Method:X-RAY DIFFRACTION (2.25 Å)
Cite:Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
J.Med.Chem., 46, 2003
1O4L
DownloadVisualize
BU of 1o4l by Molmil
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH FRAGMENT2.
Descriptor: CITRIC ACID, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC
Authors:Lange, G, Loenze, P, Liesum, A.
Deposit date:2003-06-15
Release date:2004-02-17
Last modified:2023-08-16
Method:X-RAY DIFFRACTION (1.65 Å)
Cite:Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
J.Med.Chem., 46, 2003
1O45
DownloadVisualize
BU of 1o45 by Molmil
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU84687.
Descriptor: N-ACETYL-N-[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]-3-FORMYL-O-PHOSPHONOTYROSINAMIDE, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC
Authors:Lange, G, Loenze, P, Liesum, A.
Deposit date:2003-06-15
Release date:2004-02-17
Last modified:2023-08-16
Method:X-RAY DIFFRACTION (1.8 Å)
Cite:Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
J.Med.Chem., 46, 2003
1O4F
DownloadVisualize
BU of 1o4f by Molmil
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU79073.
Descriptor: 1,2,3,4-TETRAHYDROQUINOLIN-8-YL DIHYDROGEN PHOSPHATE, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC
Authors:Lange, G, Loenze, P, Liesum, A.
Deposit date:2003-06-15
Release date:2004-02-17
Last modified:2023-11-15
Method:X-RAY DIFFRACTION (2 Å)
Cite:Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
J.Med.Chem., 46, 2003
1O4K
DownloadVisualize
BU of 1o4k by Molmil
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PASBN.
Descriptor: BENZYL 2-FORMYLPHENYL HYDROGEN PHOSPHATE, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC
Authors:Lange, G, Loenze, P, Liesum, A.
Deposit date:2003-06-15
Release date:2004-02-17
Last modified:2023-08-16
Method:X-RAY DIFFRACTION (1.57 Å)
Cite:Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
J.Med.Chem., 46, 2003
1O4A
DownloadVisualize
BU of 1o4a by Molmil
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU82197.
Descriptor: 4-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-FORMYL-BENZOIC ACID, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC
Authors:Lange, G, Loenze, P, Liesum, A.
Deposit date:2003-06-15
Release date:2004-02-17
Last modified:2023-08-16
Method:X-RAY DIFFRACTION (1.5 Å)
Cite:Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
J.Med.Chem., 46, 2003
1O41
DownloadVisualize
BU of 1o41 by Molmil
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78300.
Descriptor: 2-FORMYL-6-METHOXYPHENYL DIHYDROGEN PHOSPHATE, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC
Authors:Lange, G, Loenze, P, Liesum, A.
Deposit date:2003-06-15
Release date:2004-02-17
Last modified:2023-08-16
Method:X-RAY DIFFRACTION (1.7 Å)
Cite:Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
J.Med.Chem., 46, 2003
1O47
DownloadVisualize
BU of 1o47 by Molmil
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU82209.
Descriptor: N-ACETYL-N-[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]-4-[DIFLUORO(PHOSPHONO)METHYL]PHENYLALANINAMIDE, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC
Authors:Lange, G, Loenze, P, Liesum, A.
Deposit date:2003-06-15
Release date:2004-02-17
Last modified:2023-08-16
Method:X-RAY DIFFRACTION (1.8 Å)
Cite:Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
J.Med.Chem., 46, 2003
1O46
DownloadVisualize
BU of 1o46 by Molmil
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU90395.
Descriptor: 2-{4-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-METHOXYCARBONYL-PHENYL}-2-FLUORO-MALONIC ACID, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC
Authors:Lange, G, Loenze, P, Liesum, A.
Deposit date:2003-06-15
Release date:2004-02-17
Last modified:2023-08-16
Method:X-RAY DIFFRACTION (2 Å)
Cite:Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
J.Med.Chem., 46, 2003
1O4C
DownloadVisualize
BU of 1o4c by Molmil
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PHOSPHATE.
Descriptor: PHOSPHATE ION, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC
Authors:Lange, G, Loenze, P, Liesum, A.
Deposit date:2003-06-15
Release date:2004-02-17
Last modified:2023-11-15
Method:X-RAY DIFFRACTION (1.8 Å)
Cite:Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
J.Med.Chem., 46, 2003
1O4I
DownloadVisualize
BU of 1o4i by Molmil
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PAS219.
Descriptor: PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC, cyclohexylmethyl 2-formylphenyl hydrogen (S)-phosphate
Authors:Lange, G, Loenze, P, Liesum, A.
Deposit date:2003-06-15
Release date:2004-02-17
Last modified:2023-08-16
Method:X-RAY DIFFRACTION (1.75 Å)
Cite:Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
J.Med.Chem., 46, 2003
1O48
DownloadVisualize
BU of 1o48 by Molmil
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU85053.
Descriptor: 5-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-CARBOXYMETHYL-BENZOIC ACID, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC
Authors:Lange, G, Loenze, P, Liesum, A.
Deposit date:2003-06-15
Release date:2004-02-17
Last modified:2023-08-16
Method:X-RAY DIFFRACTION (1.55 Å)
Cite:Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
J.Med.Chem., 46, 2003

 

123>

222624

PDB entries from 2024-07-17

PDB statisticsPDBj update infoContact PDBjnumon